Exelixis, Inc. (NASDAQ:EXEL) Director George A. Scangos sold 6,500 shares of the stock in a transaction dated Thursday, November 29th. The shares were sold at an average price of $20.00, for a total transaction of $130,000.00. Following the completion of the transaction, the director now owns 1,505,481 shares of the company’s stock, valued at approximately $30,109,620. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
NASDAQ:EXEL opened at $21.50 on Tuesday. The company has a quick ratio of 8.54, a current ratio of 8.66 and a debt-to-equity ratio of 0.01. Exelixis, Inc. has a twelve month low of $13.42 and a twelve month high of $32.20. The stock has a market cap of $6.07 billion, a price-to-earnings ratio of 17.21, a price-to-earnings-growth ratio of 1.20 and a beta of 2.32.
Exelixis (NASDAQ:EXEL) last posted its earnings results on Thursday, November 1st. The biotechnology company reported $0.41 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.19 by $0.22. Exelixis had a net margin of 49.53% and a return on equity of 55.71%. The firm had revenue of $225.40 million during the quarter, compared to the consensus estimate of $174.14 million. During the same period last year, the firm posted $0.26 EPS. The firm’s revenue for the quarter was up 47.8% on a year-over-year basis. On average, research analysts forecast that Exelixis, Inc. will post 1.3 EPS for the current year.
A number of equities analysts have recently issued reports on EXEL shares. Morgan Stanley started coverage on shares of Exelixis in a report on Monday, September 10th. They issued an “underweight” rating and a $19.00 price target for the company. Goldman Sachs Group started coverage on shares of Exelixis in a report on Monday, September 17th. They issued a “neutral” rating and a $22.00 price target for the company. BidaskClub upgraded shares of Exelixis from a “strong sell” rating to a “sell” rating in a report on Saturday, September 29th. Piper Jaffray Companies dropped their target price on shares of Exelixis from $29.00 to $26.00 and set an “overweight” rating for the company in a report on Monday, November 5th. Finally, Oppenheimer set a $40.00 target price on shares of Exelixis and gave the company a “buy” rating in a report on Thursday, November 15th. Two analysts have rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. Exelixis presently has an average rating of “Buy” and an average price target of $29.44.
ILLEGAL ACTIVITY NOTICE: This report was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.com-unik.info/2018/12/04/insider-selling-exelixis-inc-exel-director-sells-6500-shares-of-stock.html.
Exelixis, Inc, a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.
Further Reading: What is Cost of Debt?
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.